Details of the Drug
General Information of Drug (ID: DMWPBKU)
| Drug Name |
N-methyllaurotetanine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Lauroscholtzine; N-Methyllaurotetanine; 2169-44-0; Rogersine; NSC 247564; CHEMBL464099; UNII-11558LRZ50; NSC 247506; 11558LRZ50; 1,2,10-Trimethoxy-6a-alpha-aporphin-9-ol; 6a-alpha-APORPHIN-9-OL, 1,2,10-TRIMETHOXY-; 4H-Dibenzo(de,g)quinolin-9-ol, 5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (S)-; Boldine 2-methyl ether; (+)-N-methyl-laurotetanine; AC1L288L; DTXSID60176073; MolPort-003-804-060; ZINC338123; NSC247506; BDBM50250422; NSC247564; AKOS032948666; NSC-247564; NSC-247506; LS-21503; W1151
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 341.4 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


